Gilead raises 2020 guidance on strong remdesivir sales

Monday, 11. January 2021 13:21

Gilead Sciences Inc. on Monday revised guidance for the full 2020, citing strong remdesivir sales as the reason for the higher revenue forecast.

According to the updated figures, Gilead now expects its product sales to land between $24,300 million and $24,350 million, while operating income is seen between $11,650 million and $11,750 million.

Earlier in December, the biopharmaceutical company acquired drugmaker MYR Pharmaceuticals for $1.39 billion.

Related Links: Gilead Sciences Inc.
Breaking the News / MD